These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Treatment of Indian Kala-azar with pentavalent antimony. Domingo P; Ferrer S; Kolle L; Muñoz C; Sambeat MA Lancet; 1995 Mar; 345(8949):584-5. PubMed ID: 7776793 [No Abstract] [Full Text] [Related]
7. [A case of antimony resistant kala-azar cured with amphotericin B]. Chen SB; Yang CM; Zhang CJ Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767 [No Abstract] [Full Text] [Related]
8. Antimony-induced cerebellar ataxia. Khalil EA; Ahmed AE; Musa AM; Hussein MH Saudi Med J; 2006 Jan; 27(1):90-2. PubMed ID: 16432602 [TBL] [Abstract][Full Text] [Related]
9. Case report: Acute renal injury as a result of liposomal amphotericin B treatment in sodium stibogluconate unresponsive visceral leishmaniasis. Zhao S; Zhang D; Li L; Mao Q Am J Trop Med Hyg; 2011 Dec; 85(6):1035-7. PubMed ID: 22144439 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapy of leishmaniasis in India. Thakur CP Indian J Pediatr; 1987; 54(1):7-10. PubMed ID: 3030933 [No Abstract] [Full Text] [Related]
11. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients. Minodier P; Retornaz K; Horelt A; Garnier JM Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228 [TBL] [Abstract][Full Text] [Related]
12. Recent advances in the treatment of visceral leishmaniasis. Davidson RN; Croft SL Trans R Soc Trop Med Hyg; 1993; 87(2):130-1, 141. PubMed ID: 8393221 [No Abstract] [Full Text] [Related]
13. Acute pancreatitis associated with sodium stibogluconate treatment in a patient with human immunodeficiency virus. Domingo P; Ferrer S; Kolle L; Muñoz C; Rodriguez P Arch Intern Med; 1996 May; 156(9):1029, 1032. PubMed ID: 8624172 [No Abstract] [Full Text] [Related]
14. ECG changes in prolonged treatment of kala-azar with antimony compounds. Pandey AK; Kumar M; Thakur CP J Assoc Physicians India; 1988 Jun; 36(6):398-9. PubMed ID: 2846508 [No Abstract] [Full Text] [Related]
15. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Kumar D; Ramesh V; Verma S; Ramam M; Salotra P Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997 [No Abstract] [Full Text] [Related]
16. Conduction defect following pentavalent antimony therapy in visceral leishmaniasis. Ahasan HA; Chowdhury MA; Azhar MA; Rafiqueuddin AK; Islam F Trop Doct; 1997 Jan; 27(1):59-61. PubMed ID: 9030031 [No Abstract] [Full Text] [Related]
17. Kala-azar in Bihar. Prasad LS Indian J Pediatr; 1987; 54(1):103-10. PubMed ID: 3030932 [No Abstract] [Full Text] [Related]
18. [Treatment of visceral leishmaniasis in children]. Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279 [TBL] [Abstract][Full Text] [Related]
19. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Thakur CP; Sinha GP; Pandey AK; Kumar N; Kumar P; Hassan SM; Narain S; Roy RK Ann Trop Med Parasitol; 1998 Jul; 92(5):561-9. PubMed ID: 9797829 [TBL] [Abstract][Full Text] [Related]
20. Challenges in the management of visceral leishmaniasis. Sundar S; Kumar A Indian Pediatr; 2005 Jun; 42(6):523-6. PubMed ID: 15995268 [No Abstract] [Full Text] [Related] [Next] [New Search]